The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have...

Descripción completa

Detalles Bibliográficos
Autores principales: Brar, Gagandeep, Shah, Manish A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724489/
https://www.ncbi.nlm.nih.gov/pubmed/31516556
http://dx.doi.org/10.1177/1756284819869767
_version_ 1783449005323190272
author Brar, Gagandeep
Shah, Manish A.
author_facet Brar, Gagandeep
Shah, Manish A.
author_sort Brar, Gagandeep
collection PubMed
description Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers.
format Online
Article
Text
id pubmed-6724489
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67244892019-09-12 The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma Brar, Gagandeep Shah, Manish A. Therap Adv Gastroenterol Review Gastric cancer is a leading cause of cancer-related death worldwide. Recent evidence suggests that gastric cancer is a complex and heterogenous disease with emerging subtypes shown to affect response to treatment and survival. Immunotherapy is an advancing field and immune checkpoint inhibitors have become standard treatment options in numerous tumor types. In this review, we discuss the current and evolving use of checkpoint blockade, focusing on the anti-PD-1 inhibitor, pembrolizumab, for use in advanced gastric and gastroesophageal cancers. SAGE Publications 2019-09-02 /pmc/articles/PMC6724489/ /pubmed/31516556 http://dx.doi.org/10.1177/1756284819869767 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Brar, Gagandeep
Shah, Manish A.
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_full The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_fullStr The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_full_unstemmed The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_short The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
title_sort role of pembrolizumab in the treatment of pd-l1 expressing gastric and gastroesophageal junction adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724489/
https://www.ncbi.nlm.nih.gov/pubmed/31516556
http://dx.doi.org/10.1177/1756284819869767
work_keys_str_mv AT brargagandeep theroleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT shahmanisha theroleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT brargagandeep roleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma
AT shahmanisha roleofpembrolizumabinthetreatmentofpdl1expressinggastricandgastroesophagealjunctionadenocarcinoma

Ejemplares similares